- Nigerian women's rights pioneer celebrated in new biopic
- Slovak PM 'able to speak' after shooting, suspected gunman charged
- Pyramids built along long-lost river, scientists discover
- London's Queen's Club to host WTA Tour event for first time in 52 years
- Paul survives chaotic ending to reach Rome Open semis
- French LGBTQ groups 'extremely concerned' over increase in attacks
- Anya Taylor-Joy praises 'unbelievable' 'Mad Max' stunt team
- Stocks waver after hitting record highs
- Green policies can be vote winners, London mayor says
- McIlroy shares early lead at emotionally testing PGA Championship
- S.Africa tells UN court Israel 'genocide' hit 'new and horrific stage'
- Man City's Ederson out of Premier League climax and FA Cup final
- 'Rappers and yodellers': Nagelsmann strikes balance in Euro 2024 squad
- England set to ban gender identity teaching in schools
- Serbia leases army HQ bombed by NATO to Trump son-in-law
- France deploys additional forces to quell New Caledonia unrest
- McIlroy faces emotional early test as PGA Championship begins
- Chelsea players 'love' Pochettino and must fight for him, says Palmer
- Germany boss Nagelsmann ignores Hummels to stick with regulars for Euros
- Sevilla great Navas to leave club in summer
- France accuses Azerbaijan of interference in New Caledonia riots
- European stocks dip from records, shrugging off gains elsewhere
- Toulouse's Chocobares eligible for Champions Cup final in spite of suspension
- Dutch EU opt-out on asylum could take 'years': Wilders to AFP
- Murray makes victorious comeback in Bordeaux
- China's Baidu posts weakest quarterly revenue growth in over a year
- EU probes Facebook, Instagram over child protection
- Inter's title party continues as off-field problems lurk
- A pariah in the West, Putin finds fans in Beijing
- Ukraine says halted Russian 'advance' in some Kharkiv zones
- Asian football body scraps term limits for top leaders
- Five Israeli troops killed by friendly fire in Gaza
- US military says aid pier anchored to Gaza beach
- Taiwan presidential banquet to showcase island's identity
- Easyjet CEO flies out in 2025 after seven years
- New Dutch coalition govt wants 'strictest' asylum policy
- Siemens to sell electrical motors business to KPS
- Lai Ching-te: from coal miner's son to Taiwan president
- Slovak PM in 'very serious' condition after assassination attempt
- France deploys troops, bans TikTok, to quell New Caledonia unrest
- Record Super Rugby try scorer Perenara backed for All Blacks return
- Indian record-breaker Chhetri to retire from international football
- Esperance, Ahly resume great African club rivalry in final
- Clutch day for Trump lawyers seeking to discredit Cohen at trial
- Turkey's 'mad honey' aphrodisiac that can knock you flat
- Xi, Putin hail ties as 'stabilising' force in chaotic world
- Consumer groups accuse Temu of manipulating online shoppers
- Premier League in the US? FIFA weighs allowing overseas games
- Xi hails Russia ties as 'conducive to peace' in Putin talks
- Celtics overpower Cavs, Mavs edge closer after beating Thunder
CMSC | -0.25% | 24.43 | $ | |
RBGPF | -1.42% | 59.7 | $ | |
NGG | 0.51% | 73.17 | $ | |
RELX | -0.16% | 43.84 | $ | |
RIO | 1.55% | 71.44 | $ | |
GSK | -0.49% | 45.1009 | $ | |
SCS | 2.89% | 14.015 | $ | |
RYCEF | -2.05% | 5.33 | $ | |
CMSD | -0.05% | 24.36 | $ | |
BCE | -0.46% | 34.41 | $ | |
AZN | -0.12% | 76.88 | $ | |
BTI | 0.93% | 31.615 | $ | |
VOD | 1.22% | 9.759 | $ | |
BP | -0.32% | 37.205 | $ | |
JRI | -0.04% | 11.645 | $ | |
BCC | -0.51% | 140.14 | $ |
French-Canadian gets 'Oscars of Science' prize for cancer treatment
French-Canadian scientist Michel Sadelain was awarded an "Oscars of Science" prize in Los Angeles on Saturday for his research into genetically modifying immune cells to fight cancer.
The genetic engineer was awarded the Breakthrough Prize at a glitzy ceremony attended by tech giants such as Elon Musk and Bill Gates, and an array of celebrities including Jessica Chastain, Robert Downey Jr. and Bradley Cooper.
His work has led to the development of a new form of therapy called CAR-T that has shown exceptional efficacy against certain blood cancers.
"This prize is an extraordinary recognition," Sadelain told AFP on the red carpet at the Oscars Museum. "It's all the more of an honor because ... my scientific colleagues told me for a long time that it would never work."
Launched in 2010, the Breakthrough Prize awards "the world's most brilliant minds" in fields including life sciences, fundamental physics and mathematics, styling itself as the Silicon Valley-backed answer to the Nobels.
Dubbed the "Oscars for Science", founding sponsors include Sergey Brin, Priscilla Chan and Mark Zuckerberg.
Sadelain will split the $3 million prize money with American immunologist Carl June, who also led groundbreaking research into the field independently of his co-winner.
"The greatest pleasure, however, is to see patients... who no longer had a chance and who thank us, who are alive today thanks to CAR-T cells," said Sadelain.
Sadelain studied medicine in Paris, then immunology in Canada, before taking up postdoctoral research at the Massachusetts Institute of Technology in 1989.
- 'Living drugs' -
At the time, there was great interest in developing vaccines to train the immune system to recognize and destroy cancer cells, in the same way it can be taught to tackle foreign invaders such as bacteria and viruses.
After moving to the Memorial Sloan Kettering Cancer Center in New York, Sadelain developed a way to use a disabled virus to genetically reprogram human T-cells, so that they grew claw-like structures called antigen receptors, allowing the T-cells to target specific cancer cells.
Beyond recognizing the cancer, these Chimeric Antigen Receptor (CAR) T-cells, as Sadelain named them, were also given genetic instructions to enter a killing mode and to multiply, growing an army inside the body to eliminate the enemy.
Thanks to the groundwork laid by Sadelain and June, half a dozen US-approved CAR-T cell therapies are now available, and hundreds more trials are underway.
Patients' own T-cells are collected, modified outside the body, and then infused back into the blood, creating so-called "living drugs".
The treatment has proved effective against lymphoma, certain leukaemias and myeloma, a serious and complex blood cancer. Sadelain hopes that research will make it possible to "apply this treatment to other cancers".
One of the main challenges is to lower the cost of treatment, which costs over $500,000 -- a sum generally covered by insurance.
Around 20 other scientists were honored on Saturday at the Breakthrough Prize, in various categories.
Some of the research awarded included effective drugs to treat the underlying cause of cystic fibrosis, a genetic disorder that affects the lungs, and the discovery of the most common genetic causes of Parkinson's disease.
F.Pavlenko--BTB